Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase

1 hour ago 3

Jonathan Ponciano, The Motley Fool

Sun, May 17, 2026 astatine 3:46 PM CDT 4 min read

On May 15, 2026, Boxer Capital Management disclosed a caller presumption successful Corvus Pharmaceuticals (NASDAQ:CRVS), acquiring 1,100,000 shares successful the archetypal 4th for an estimated $17.55 cardinal based connected quarterly mean pricing.

What happened

According to a May 15, 2026, SEC filing, Boxer Capital Management disclosed a caller presumption successful Corvus Pharmaceuticals (NASDAQ:CRVS) by purchasing 1,100,000 shares implicit the archetypal quarter. The estimated transaction worth is $17.55 million, calculated utilizing the mean closing terms for the period. The money reported a quarter-end presumption worth of $16.09 cardinal for Corvus Pharmaceuticals, reflecting some stock accumulation and terms shifts.

What other to cognize

This was a caller presumption for Boxer Capital Management, representing 2.11% of March 31, 2026, reportable AUM.
Top 5 holdings aft the filing:
- NASDAQ:TNGX: $227.53 cardinal (29.9% of AUM)
- NASDAQ:KOD: $51.88 cardinal (6.8% of AUM)
- NASDAQ:RVMD: $48.62 cardinal (6.4% of AUM)
- NASDAQ:KYMR: $27.41 cardinal (3.6% of AUM)
- NASDAQ:CELC: $25.68 cardinal (3.4% of AUM)
As of May 14, 2026, Corvus Pharmaceuticals shares were priced astatine $13.66, up 250% implicit the past year, outperforming the S&P 500’s astir 25% gain.

Company overview

Metric

Value

Price (as of marketplace adjacent May 14, 2026)	$13.66
Market Capitalization	$1 billion
Net Income (TTM)	($15.3 million)

Company snapshot

Corvus Pharmaceuticals develops immuno-oncology therapies, with pb candidates including Mupadolimab (CPI-006) for non-small compartment lung crab and caput and cervix cancers, CPI-818 for malignant T-cell lymphomas, and Ciforadenant (CPI-444) for precocious renal compartment cancer.
The institution operates a clinical-stage biopharmaceutical model, generating worth done the improvement and imaginable commercialization of proprietary monoclonal antibodies and small-molecule drugs targeting crab and immune-related diseases.
Corvus Pharmaceuticals collaborates strategically with partners to beforehand its pipeline and code unmet needs successful oncology and immune-related conditions.

Corvus Pharmaceuticals is simply a clinical-stage biotechnology institution focused connected processing innovative immunotherapies for crab treatment. Leveraging a pipeline of monoclonal antibodies and tiny molecule antagonists, the institution aims to code unmet needs successful oncology done strategical probe and objective development. Its competitory borderline lies successful its targeted attack to immune modulation and strategical collaborations to beforehand its portfolio.

What this transaction means for investors

Boxer Capital’s willingness to physique a sizable involvement successful Corvus during a beauteous monolithic tally for the firm’s banal surely seems similar a beardown ballot of confidence. Corvus has progressively shifted capitalist attraction toward atopic dermatitis, wherever caller Phase 1 information showed durable responses without important rebound aft attraction stopped. In 1 cohort, 75% of patients achieved EASI 75 responses, portion the institution besides highlighted biomarker information suggesting the imaginable for “drug-free remissions.” The institution has already launched a Phase 2 proceedings expected to enroll astir 200 patients.

Financially, Corvus ended the 4th with $236.7 cardinal successful currency and marketable securities aft raising astir $189 cardinal earlier this year, which absorption says should money operations into the 2nd 4th of 2028. Meanwhile, the institution posted a quarterly nett nonaccomplishment of $13.7 cardinal arsenic R&D spending climbed alongside expanding trials.

For semipermanent investors, the cardinal question going guardant is whether soquelitinib’s aboriginal immune-reset communicative tin clasp up successful larger studies. If it does, Corvus could go overmuch much than a tiny oncology biotech.

Read Entire Article